Senator seeks anti-Zohydro legislation

Share this article:

Painkiller Zohydro continues to come under attack. The latest challenger: Senator Joe Manchin.

Regulatory Focus reports that the Democrat from West Virginia has sponsored the "Act to Ban Zohydro" bill, which would require the drug to be pulled from the market within 45 days if it clears both Congressional chambers.

RF says Manchin's move is a standout for two reasons, the first being that the publication cannot find any  regulatory history in which an act of Congress has overturned an FDA decision. RF notes that Congress tried and failed to pass legislation against RU-486, which is used in abortions, in 2003.

The line of anti-Zohydro activity includes Manchin's proposed bill as well as a series of letters from senators including ones from New York Democrat Charles Schumer and Senate Majority Leader Mitch McConnell (R-Kentucky).

Twenty-eight attorneys general have also pressed the FDA to change its mind, but the regulator, which is a subset of the Department of Health and Human Services, is standing firm: FDA Commissioner Margaret Hamburg defended her agency's approval of Zohydro before the Senate Committee on Health Education, Labor and Pensions Committee last Thursday.  “We recognize that it is a powerful drug, but we also believe that if effectively used, it serves an important and unique niche with respect to pain medication and it meets the standards for safety and efficacy,” she told the panel.

Contributing to the Zohydro uproar is a marked uptick in painkiller prescriptions and abuse that has put local communities on edge. Critics say Zohydro runs counter to efforts to curb use and abuse because its formulation does not inhibit a user's ability to manipulate the drug to get high. Regulations have created an environment that allows drugmakers to push a branded drug off the generics pathway if the manufacturer can make a more abuse-resistant version. Purdue Pharma has successfully played this angle, while Endo has not.

Scrutiny has not deterred innovators, as seen by Friday's news that the FDA approved Mallinckrodt's opioid painkiller Xartemis. This controlled release oral oxycodone-acetaminophen combination was approved for acute pain for patients who cannot take non-opioid alternatives.

Mallinckrodt acknowledges in a statement that the label does not include any abuse-deterrence formula information but says it “will continue working closely with the FDA to develop more data to characterize abuse-deterrence features of Xartemis XR,” which uses Depomed's Acuform drug delivery technology.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.

Study says statins not enough for diabetic hearts

Researchers using an experimental test have discovered that the 50% of surveyed diabetics may also have undetected heart muscle damage.